Last updated: 11/17/2026 08:20:26

A Study on the Safety and Immune response of a Urinary Tract Infection (UTI) Vaccine in Adults 18-64 Years of age and Clinical Efficacy in Females 18-64 Years of Age

GSK study ID
219685
Clinicaltrials.gov ID
EudraCT ID
Not applicable
EU CT Number
Trial status
Active, not recruiting
Active, not recruiting
Overview
Eligibility
Locations
Study documents
Results summary
Plain language summaries
Additional information

Trial overview

Official title: A Seamless Phase 1/2, Observer-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Safety and Immunogenicity of a UTI Vaccine when Administered to Adults 18 through 64 Years of Age and Clinical Efficacy when Administered to Females 18 through 64 Years of Age
Trial description: The purpose of this study is to assess safety, reactogenicity, and immune response of the candidate UTI vaccine compared to placebo in adults between and including 18-64 years of age (YOA), and to perform a preliminary evaluation of clinical efficacy in females between and including 18-64 YOA.
Primary purpose:
Prevention
Trial design:
Sequential Assignment
Masking:
Triple (Participant, Investigator, Outcomes Assessor)
Allocation:
Randomized
Primary outcomes:

Part 1 and 2: Number of participants reporting solicited administration site adverse events (AEs)

Timeframe: During the 7 days follow-up period post-Dose 1 (study intervention administered at Day 1)

Part 1 and 2: Number of participants reporting solicited administration site AEs

Timeframe: During the 7 days follow-up period post-Dose 2 (study intervention administered at Day 61)

Part 1 and 2: Number of participants reporting solicited systemic AEs

Timeframe: During the 7 days follow-up period post-Dose 1 (study intervention administered at Day 1)

Part 1 and 2: Number of participants reporting solicited systemic AEs

Timeframe: During the 7 days follow-up period post-Dose 2 (study intervention administered at Day 61)

Part 1 and 2: Number of participants reporting unsolicited AEs

Timeframe: During the 30 days follow-up period post-Dose 1 (study intervention administered at Day 1)

Part 1 and 2: Number of participants reporting unsolicited AEs

Timeframe: During the 30 days follow-up period post-Dose 2 (study intervention administered at Day 61)

Part 1 and 2: Number of participants reporting any immediate unsolicited AEs

Timeframe: During the 60 minutes follow-up period post-Dose 1 (study intervention administered at Day 1)

Part 1 and 2: Number of participants reporting any immediate unsolicited AEs

Timeframe: During the 60 minutes follow-up period post-Dose 2 (study intervention administered at Day 61)

Part 1 and 2: Number of participants reporting serious adverse events (SAEs)

Timeframe: From Day 1 (Dose 1 administration) until Day 426 (end of follow-up)

Part 1 and 2: Number of participants reporting potential immune-mediated diseases (pIMDs) leading to study withdrawal

Timeframe: From Day 1 (Dose 1 administration) until Day 426 (end of follow-up)

Part 1 and 2: Number of participants reporting medically-attended adverse events (MAAEs) leading to study withdrawal

Timeframe: From Day 1 (Dose 1 administration) until Day 426 (end of follow-up)

Part 1 and 2: Number of participants reporting AEs leading to study withdrawal

Timeframe: From Day 1 (Dose 1 administration) until Day 426 (end of follow-up)

Part 1: Number of participants with hematology or biochemistry abnormalities or changes in baseline value

Timeframe: At 7 days post-Dose 1 (Day 8) compared with baseline (pre-Dose 1, Day 1)

Part 1: Number of participants with hematology or biochemistry abnormalities or changes in baseline value

Timeframe: At 7 days post-Dose 2 (Day 68) compared with Day 61 (pre-Dose 2)

Part 2: Incidence rate (IR) of the first occurrence of a urine culture confirmed UTI due to E. coli in the investigational group compared to the IR in placebo group

Timeframe: From 14 days (Day 75) up to 12 months (Day 426) post-Dose 2

Secondary outcomes:

Part 2: IR of the total number of occurrences of urine culture confirmed UTIs due to E. coli in the investigational group compared to the IR in placebo group

Timeframe: From 14 days (Day 75) up to 12 months (Day 426) post-Dose 2

Part 2: IR of the first occurrence of a urine culture confirmed UTI due to E. coli in the investigational group compared to the IR in placebo group

Timeframe: From 14 days post-Dose 1 (Day 15) and up to the day before administration of Dose 2 (Day 60) or, for participants receiving only Dose 1, up to the end of the study (Day 426)

Part 2: IR of the total number of occurrences of urine culture confirmed UTIs due to E. coli in the investigational group compared to the IR in placebo group

Timeframe: From 14 days post-Dose 1 (Day 15) and up to the day before administration of Dose 2 (Day 60) or, for participants receiving only Dose 1, up to the end of the study (Day 426)

Interventions:
Combination product: Candidate UTI vaccine low dose formulation 1
Combination product: Candidate UTI vaccine low dose formulation 2
Combination product: Candidate UTI vaccine medium dose formulation 1
Combination product: Candidate UTI vaccine medium dose formulation 2
Combination product: Candidate UTI vaccine high dose formulation 1
Combination product: Candidate UTI vaccine high dose formulation 2
Combination product: Candidate UTI vaccine HTD formulation 2
Combination product: Placebo
Enrollment:
465
Primary completion date:
2027-03-05
Observational study model:
Not applicable
Time perspective:
Not applicable
Clinical publications:
Not applicable
Medical condition
Urinary Tract Infections
Product
Not applicable
Collaborators
Not applicable
Study date(s)
November 2024 to May 2027
Type
Interventional
Phase
1/2

Participation criteria

Sex
Female & Male
Age
18 - 64 Years
Accepts healthy volunteers
Yes
  • Participants, who, in the opinion of the investigator, can and will comply with the requirements of the protocol.
  • Written informed consent obtained from the participant prior to performance of any study-specific procedure.
  • Medical conditions:
  • History of any reaction or hypersensitivity likely to be exacerbated by any component of the study intervention(s).

Trial location(s)

Location
Status
Contact us
Contact us
Location
GSK Investigational Site
Lenexa, KS, United States, 66219
Status
Unmapped
Location
GSK Investigational Site
Rochester, NY, United States, 14609
Status
Unmapped
Location
GSK Investigational Site
Wenatchee, WA, United States, 98801-2028
Status
Unmapped
Location
GSK Investigational Site
Johannesburg, South Africa, 2113
Status
Unmapped
Location
GSK Investigational Site
Seattle, WA, United States, 98104-2725
Status
Unmapped
Location
GSK Investigational Site
Weatherford, TX, United States, 76086
Status
Unmapped
Location
GSK Investigational Site
Secaucus, NJ, United States, 07094-2925
Status
Unmapped
Location
GSK Investigational Site
Soshanguve, South Africa, 0152
Status
Study Complete
Location
GSK Investigational Site
Covington, LA, United States, 70433
Status
Unmapped
Location
GSK Investigational Site
San Juan, PR, United States, 00917-3104
Status
Unmapped
Location
GSK Investigational Site
Anzegem, Belgium, 8570
Status
Unmapped
Location
GSK Investigational Site
BARCELONA, Barcelona, Spain, 08025
Status
Unmapped
Location
GSK Investigational Site
Houston, TX, United States, 77061-1337
Status
Unmapped
Location
GSK Investigational Site
Kluisbergen, Belgium, 9690
Status
Unmapped
Location
GSK Investigational Site
Mechelen, Belgium, 2800
Status
Unmapped
Location
GSK Investigational Site
Philadelphia, PA, United States, 19107
Status
Unmapped
Location
GSK Investigational Site
VIC, Barcelona, Spain, 08500
Status
Unmapped
Location
GSK Investigational Site
MOstoles, Spain, 28938
Status
Unmapped
Location
GSK Investigational Site
MADRID, Madrid, Spain, 28006
Status
Unmapped
Location
GSK Investigational Site
Ekurhuleni, South Africa, 1459
Status
Unmapped
Location
GSK Investigational Site
Barcelona, Spain, 08907
Status
Unmapped
Location
GSK Investigational Site
Ciudad Autonoma de Buenos Aires, Argentina, C1128AAF
Status
Unmapped
Location
GSK Investigational Site
Madrid, Spain, 28040
Status
Unmapped
Location
GSK Investigational Site
Durban, Kwazulu Natal, South Africa, 4052
Status
Unmapped
Location
GSK Investigational Site
Ieper, Belgium, 8900
Status
Unmapped
Location
GSK Investigational Site
Barcelona, Spain, 08023
Status
Unmapped
Location
GSK Investigational Site
Buenos Aires, Argentina, C1425AGC
Status
Unmapped
Location
GSK Investigational Site
Brussels, Belgium, 1070
Status
Unmapped
Location
GSK Investigational Site
Madrid, Spain, 28041
Status
Unmapped
Location
GSK Investigational Site
Madrid, Spain, 28046
Status
Unmapped
Location
GSK Investigational Site
BARCELONA, Barcelona, Spain, 08003
Status
Unmapped
Location
GSK Investigational Site
Ciudad Autonoma Buenos Aires, Argentina, C1002ABJ
Status
Unmapped
Location
GSK Investigational Site
Madrid, Spain, 28035
Status
Unmapped
Location
GSK Investigational Site
La Plata, Argentina, B1900AVG
Status
Unmapped
Location
GSK Investigational Site
Gent, Oost-Vlaanderen, Belgium, 9000
Status
Unmapped

Study documents

No study documents available.

Results overview

Study Results yet to be posted

Recruitment status
Active, not recruiting
Actual primary completion date
Not applicable
Actual study completion date
Not applicable

Plain language summaries

Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.

Additional information about the trial

Additional information
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website